Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease or ulcerative colitis. Since their approval, the indications for these medical drugs have steadily increased, but recently safety concerns have also been raised.
This article was originally published on MedicalXpress.com